Back to top

Analyst Blog

Sanofi (SNY - Analyst Report) and partner Regeneron Pharmaceuticals, Inc. (REGN - Analyst Report) recently announced that positive data from a phase IIa study evaluating dupilumab (REGN668/SAR231893) for moderate-to-severe allergic asthma was published in the New England Journal of Medicine.

The study (n = 104) evaluated the efficacy and safety of dupilumab in patients suffering from moderate-to-severe persistent asthma whose disease was inadequately controlled by inhaled glucocorticosteroids (ICS) and long-acting beta agonist (LABA) therapy. Additionally the asthma patients had elevated blood or sputum eosinophils.

As per study results, 87% reduction in the incidence of asthma exacerbations were observed in the dupilumab arm as compared to placebo. Moreover, dupilumab demonstrated statistically significant improvements in lung function and other asthma control parameters.

We note that Sanofi and Regeneron Pharma are also evaluating the candidate for treating patients suffering from moderate-to-severe atopic dermatitis (AD) who did not receive sufficient benefit with existing topical treatments. In Mar 2013, the companies presented encouraging data from two phase Ib trials evaluating dupilumab for AD.

The randomized phase Ib trials (n = 67) assessed the safety of dupilumab at three different doses (75mg, 150mg, 300mg) for 8 weeks. The companies also evaluated dupilumab in other parameters including efficacy, pharmacokinetic and biomarker.

Sanofi carries a Zacks Rank #4 (Sell). We remain concerned about the generic erosion confronting most of Sanofi’s key drugs including Plavix, Avapro, Lovenox, Taxotere, Eloxatin and Xatral. The genericization of Avapro and Plavix is expected to negatively impact Sanofi’s business net income by around €800 million in the first half of 2013.

Currently, companies like Santarus, Inc. and Jazz Pharmaceuticals (JAZZ - Analyst Report) look attractive. Both the stocks carry a  Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 26.65 +8.82%
CENTURY ALU… CENX 26.97 +7.97%
CANADIAN SO… CSIQ 37.62 +6.15%
BANCO DO BR… BDORY 16.47 +6.05%
TESLA MOTOR… TSLA 283.75 +5.21%